

SCIENTIFIC OPINION

Scientific Opinion on the substantiation of health claims related to iodine and contribution to normal cognitive and neurological function (ID 273), contribution to normal energy-yielding metabolism (ID 402), and contribution to normal thyroid function and production of thyroid hormones (ID 1237) pursuant to Article 13(1) of Regulation (EC) No 1924/2006¹

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)^{2,3}

European Food Safety Authority (EFSA), Parma, Italy

SUMMARY

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to iodine and contribution to normal cognitive and neurological function, contribution to normal energy-yielding metabolism, and contribution to normal thyroid function and production of thyroid hormones. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The food constituent that is the subject of the health claims is iodine. The Panel considers that iodine is sufficiently characterised.

Contribution to normal cognitive and neurological function

The claimed effect is “neurological/mental and cognitive development (including *in utero*)”. The target population is assumed to be the general population. In the context of the clarifications provided by Member States, the Panel assumes that the claimed effect is related to normal cognitive and

¹ On request from the European Commission, Question No EFSA-Q-2008-1060, EFSA-Q-2008-1189, EFSA-Q-2008-1975, adopted on 10 September 2010.

² Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu

³ Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.

Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to iodine and contribution to normal cognitive and neurological function (ID 273), contribution to normal energy-yielding metabolism (ID 402), and contribution to normal thyroid function and production of thyroid hormones (ID 1237) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1800. [15 pp.]. doi:10.2903/j.efsa.2010.1800. Available online: www.efsa.europa.eu/efsajournal.htm

neurological function. The Panel considers that contribution to normal cognitive and neurological function is a beneficial physiological effect.

Iodine deficiency disorders encompass suboptimal neurological function, apathy and mental sluggishness.

A cause and effect relationship has been established between the dietary intake of iodine and contribution to normal cognitive and neurological function.

Contribution to normal energy-yielding metabolism

The claimed effect is “energy metabolism”. The target population is assumed to be the general population.

A claim on iodine and normal energy-yielding metabolism has already been assessed with a favourable outcome.

Contribution to normal thyroid function and production of thyroid hormones

The claimed effect is “body functions”. The target population is assumed to be the general population. In the context of the clarifications provided by Member States, the Panel assumes that the claimed effect is related to normal thyroid function and production of thyroid hormones.

A claim on iodine and normal thyroid function and production of thyroid hormones has already been assessed with a favourable outcome.

Conditions and possible restrictions of use

The Panel considers that, in order to bear the claims, a food should be at least a source of iodine as per Annex to Regulation (EC) No 1924/2006. Such amounts can be easily consumed as part of a balanced diet. The target population is the general population.

KEY WORDS

Iodine, neurological function, cognitive function, thyroid function, thyroid hormones, energy-yielding metabolism, health claims.

TABLE OF CONTENTS

Summary	1
Table of contents	3
Background as provided by the European Commission	4
Terms of reference as provided by the European Commission	4
EFSA Disclaimer.....	4
Information as provided in the consolidated list	5
Assessment	5
1. Characterisation of the food/constituent	5
2. Relevance of the claimed effect to human health.....	5
2.1. Contribution to normal cognitive and neurological function (ID 273).....	5
2.2. Contribution to normal energy-yielding metabolism (ID 402).....	6
2.3. Contribution to normal thyroid function and production of thyroid hormones (ID 1237).....	6
3. Scientific substantiation of the claimed effect	6
3.1. Contribution to normal cognitive and neurological function (ID 273).....	6
4. Panel's comments on the proposed wording.....	7
4.1. Contribution to normal cognitive and neurological function (ID 273).....	7
5. Conditions and possible restrictions of use	7
Conclusions	7
Documentation provided to EFSA	8
References	8
Appendices	9

BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

See Appendix A

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

See Appendix A

EFSA DISCLAIMER

See Appendix B

INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST

The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006⁴ submitted by Member States contains main entry claims with corresponding conditions of use and literature for similar health claims. EFSA has screened all health claims contained in the original consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria established by the NDA Panel to identify claims for which EFSA considered sufficient information had been provided for evaluation and those for which more information or clarification was needed before evaluation could be carried out⁵. The clarifications which were received by EFSA through the screening process have been included in the consolidated list. This additional information will serve as clarification to the originally provided information. The information provided in the consolidated list for the health claims which are the subject of this opinion is tabulated in Appendix C.

ASSESSMENT

1. Characterisation of the food/constituent

The food constituent that is the subject of the health claims is iodine, which is a well recognised nutrient and is measurable in foods by established methods.

Iodine occurs naturally in foods and is authorised for addition to foods (Annex I of the Regulation (EC) No 1925/2006⁶ and Annex I of Directive 2002/46/EC⁷). This evaluation applies to iodine naturally present in foods and those forms authorised for addition to foods (Annex II of the Regulation (EC) No 1925/2006 and Annex II of Directive 2002/46/EC).

The Panel considers that the food constituent, iodine, which is the subject of the health claims, is sufficiently characterised.

2. Relevance of the claimed effect to human health

2.1. Contribution to normal cognitive and neurological function (ID 273)

The claimed effect is “neurological/mental and cognitive development (including *in utero*)”. The Panel assumes that the target population is the general population.

In the context of the clarifications provided by Member States, the Panel assumes that the claimed effect is related to normal cognitive and neurological function.

The Panel considers that contribution to normal cognitive and neurological function is a beneficial physiological effect.

⁴ Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.

⁵ Briefing document for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims: <http://www.efsa.europa.eu/en/ndameetings/docs/nda100601-ax01.pdf>

⁶ Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38.

⁷ Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57.

2.2. Contribution to normal energy-yielding metabolism (ID 402)

The claimed effect is “energy metabolism”. The Panel assumes that the target population is the general population.

A claim on iodine and normal energy-yielding metabolism has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009).

2.3. Contribution to normal thyroid function and production of thyroid hormones (ID 1237)

The claimed effect is “body functions”. The Panel assumes that the target population is the general population.

In the context of the clarifications provided by Member States, the Panel assumes that the claimed effect is related to normal thyroid function and production of thyroid hormones.

A claim on iodine and normal thyroid function and production of thyroid hormones has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009).

3. Scientific substantiation of the claimed effect

Iodine is an essential constituent of the thyroid hormones, which have important modifying or permissive roles in growth and development, and there is a large body of evidence indicating a crucial role for iodine in growth and development (Sadler et al., 1999; IoM, 2002; Garrow et al., 2000; WHO, 2001; Strain and Cashman, 2009). The biological function of the thyroid hormones encompasses the regulation of energy-yielding metabolism and endocrine function by cellular oxidation, thermoregulation, intermediary metabolism, protein and enzyme synthesis, nitrogen retention, gluconeogenesis and pituitary gonadotropins (Houston, 1998; SCF, 2002). A wide spectrum of iodine deficiency disorders has been observed, depending on the degree of deficiency and the life stage at which the deficiency occurs. These disorders include goitre, hypothyroidism and impaired mental function, including the most severe forms of endemic cretinism (congenital, severe, irreversible mental and growth retardation). Other symptoms of severe iodine deficiency disorders (arising from iodine deficiency in the foetus) include deaf-mutism, squint, disorders of stance and gait, and dry skin and swollen subcutaneous tissue (Delange, 2000; EVM, 2003; WHO, 2007). Most countries in the world have some degree of iodine deficiency disorders including several European countries (Stanbury et al., 1998; WHO, 1999; Delange, 2002, WHO, 2007).

3.1. Contribution to normal cognitive and neurological function (ID 273)

Iodine deficiency disorders encompass suboptimal neurological function, apathy and mental sluggishness (SCF, 2002). The WHO (2001) describes a wide spectrum of iodine deficiency disorders which include retarded mental and physical development in children and adolescents, and impaired mental function and reduced cognitive capacity for people of all ages.

The Panel concludes that a cause and effect relationship has been established between the dietary intake of iodine and contribution to normal cognitive and neurological function.

4. Panel's comments on the proposed wording

4.1. Contribution to normal cognitive and neurological function (ID 273)

The Panel considers that the following wording reflects the scientific evidence: "Iodine contributes to normal cognitive and neurological function".

5. Conditions and possible restrictions of use

The Panel considers that in order to bear the claims a food should be at least a source of iodine as per Annex to Regulation (EC) No 1924/2006. Tolerable Upper Intake Levels (ULs) have been established for iodine in children, adolescents, adults, pregnant and lactating women (SCF, 2002). The target population is the general population.

CONCLUSIONS

On the basis of the data presented, the Panel concludes that:

- The food constituent, iodine, which is the subject of the health claims, is sufficiently characterised.

Contribution to normal cognitive and neurological function (ID 273)

- The claimed effect is "neurological/mental and cognitive development (including *in utero*)". The target population is assumed to be the general population. Contribution to normal cognitive and neurological function is a beneficial physiological effect.
- A cause and effect relationship has been established between the dietary intake of iodine and contribution to normal cognitive and neurological function.
- The following wording reflects the scientific evidence: "Iodine contributes to normal cognitive and neurological function".

Contribution to normal energy-yielding metabolism (ID 402)

- The claimed effect is "energy metabolism". The target population is assumed to be the general population.
- A claim on iodine and normal energy-yielding metabolism has already been assessed with a favourable outcome.

Contribution to normal thyroid function and production of thyroid hormones (ID 1237)

- The claimed effect is "body functions". The target population is assumed to be the general population. In the context of the clarifications provided by Member States, it is assumed that the claimed effect is related to normal thyroid function and production of thyroid hormones.
- A claim on iodine and normal thyroid function and production of thyroid hormones has already been assessed with a favourable outcome.

Conditions and possible restrictions of use

- In order to bear the claims a food should be at least a source of iodine as per Annex to Regulation (EC) No 1924/2006. Such amounts can be easily consumed as part of a balanced diet. The target population is the general population.

DOCUMENTATION PROVIDED TO EFSA

Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1060, EFSA-Q-2008-1189, EFSA-Q-2008-1975). The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The full list of supporting references as provided to EFSA is available on: <http://www.efsa.europa.eu/panels/nda/claims/article13.htm>.

REFERENCES

- Delange F, 2000. The role of iodine in brain development. *Proceedings of the Nutrition Society*, 59, 75-79.
- Delange F, 2002. Iodine deficiency in Europe and its consequences: an update. *European Journal of Nuclear Medicine and Molecular Imaging*, 29, S404-S416.
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009. Scientific Opinion on substantiation of health claims related to iodine and thyroid function and production of thyroid hormones (ID 274), energy-yielding metabolism (ID 274), maintenance of vision (ID 356), maintenance of hair (ID 370), maintenance of nails (ID 370), and maintenance of skin (ID 370) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. *EFSA Journal*, 7(9):1214, 17 pp.
- EVM (Expert Group on Vitamins and Minerals) 2003. *Safe Upper Levels for Vitamins and Minerals*.
- Garrow JS, James WPT and Ralph A, 2000. *Human Nutrition and Dietetics*. Churchill Livingstone, London, Edinburgh.
- Houston R, 1998. Iodine. *Physiology, Dietary Sources and Requirements. Deficiency Disorders*. In: *Encyclopedia of human nutrition*. Eds Sadler MJ, Strain JJ and Caballero B. Academic Press, San Diego, 1138–1146.
- IoM (Institute of Medicine), 2002. *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. National Academy Press, Washington D.C.
- Sadler MJ, Strain and Caballero B, 1999. *Encyclopedia of Human Nutrition*, Academic Press, San Diego.
- SCF (Scientific Committee on Food), 2002. *Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Iodine*.
- Stanbury JB, Ermans AE, Bourdoux P, Todd C, Tonglet R, Vidor G, Braverman LE and Medeiros-Neto G, 1998. Iodine-induced hyperthyroidism: Occurrence and epidemiology. *Thyroid*, 8, 83-100.
- Strain JJ and Cashman KD, 2009. *Minerals and trace elements*. In: *Introduction to Human Nutrition*. Eds Gibney MJ, Lanham-New SA, Cassidy A and Vorster HH, Wiley-Blackwell, Chichester.
- WHO (World Health Organization), 1999. *Progress towards the elimination of iodine deficiency disorders (IDD)*.
- WHO (World Health Organization), 2001. *Assessment of iodine deficiency disorders and monitoring. Their elimination. A guide for programme managers*.
- WHO (World Health Organization), 2007. *Iodine deficiency in Europe. A continuing public health problem*. Published jointly with UNICEF.

APPENDICES

APPENDIX A

BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

The Regulation 1924/2006 on nutrition and health claims made on foods⁸ (hereinafter "the Regulation") entered into force on 19th January 2007.

Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted health claims other than those referring to the reduction of disease risk and to children's development and health. This Community list shall be adopted through the Regulatory Committee procedure and following consultation of the European Food Safety Authority (EFSA).

Health claims are defined as "any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health".

In accordance with Article 13 (1) health claims other than those referring to the reduction of disease risk and to children's development and health are health claims describing or referring to:

- a) the role of a nutrient or other substance in growth, development and the functions of the body; or
- b) psychological and behavioural functions; or
- c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the sense of hunger or an increase in the sense of satiety or to the reduction of the available energy from the diet.

To be included in the Community list of permitted health claims, the claims shall be:

- (i) based on generally accepted scientific evidence; and
- (ii) well understood by the average consumer.

Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 January 2008 accompanied by the conditions applying to them and by references to the relevant scientific justification. These lists have been consolidated into the list which forms the basis for the EFSA consultation in accordance with Article 13 (3).

ISSUES THAT NEED TO BE CONSIDERED

IMPORTANCE AND PERTINENCE OF THE FOOD⁹

Foods are commonly involved in many different functions¹⁰ of the body, and for one single food many health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for functions affected by a large number of dietary factors it should be considered whether a reference to a single food is scientifically pertinent.

⁸ OJ L12, 18/01/2007

⁹ The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.

¹⁰ The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).

It should also be considered if the information on the characteristics of the food contains aspects pertinent to the beneficial effect.

SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE

Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims should be scientifically substantiated by taking into account the totality of the available scientific data, and by weighing the evidence, and shall demonstrate the extent to which:

- (a) the claimed effect of the food is beneficial for human health,
- (b) a cause and effect relationship is established between consumption of the food and the claimed effect in humans (such as: the strength, consistency, specificity, dose-response, and biological plausibility of the relationship),
- (c) the quantity of the food and pattern of consumption required to obtain the claimed effect could reasonably be achieved as part of a balanced diet,
- (d) the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the application for authorisation of health claims consistent criteria for the potential sources of scientific data. Such sources may not be available for all health claims. Nevertheless it will be relevant and important that EFSA comments on the availability and quality of such data in order to allow the regulator to judge and make a risk management decision about the acceptability of health claims included in the submitted list.

The scientific evidence about the role of a food on a nutritional or physiological function is not enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified functions in the body in a way which is relevant to health. Although an appreciation of the beneficial effect in relation to the nutritional status of the European population may be of interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or physiological effect for that population should not, however, condition such considerations.

Different types of effects can be claimed. Claims referring to the maintenance of a function may be distinct from claims referring to the improvement of a function. EFSA may wish to comment whether such different claims comply with the criteria laid down in the Regulation.

WORDING OF HEALTH CLAIMS

Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. However, the wording of health claims should also be commented by EFSA in its opinion.

There is potentially a plethora of expressions that may be used to convey the relationship between the food and the function. This may be due to commercial practices, consumer perception and linguistic or cultural differences across the EU. Nevertheless, the wording used to make health claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet.

In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or other substance in growth, development and the functions of the body". Therefore, the requirement to

describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the body should be carefully considered.

The specificity of the wording is very important. Health claims such as "Substance X supports the function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the various functions of the joints is described or referred to contrary to the latter example which specifies this by using the word "flexibility".

The clarity of the wording is very important. The guiding principle should be that the description or reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or "helps".

In addition, for functions affected by a large number of dietary factors it should be considered whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the scientific evidence.

Similar alternative wordings as mentioned above are used for claims relating to different relationships between the various foods and health. It is not the intention of the regulator to adopt a detailed and rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is not required that EFSA comments on each individual wording for each claim unless the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and comment generally on such elements relating to wording to ensure the compliance with the criteria laid down in the Regulation.

In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average consumer should be recalled. In addition, such assessment should take into account the particular perspective and/or knowledge in the target group of the claim, if such is indicated or implied.

TERMS OF REFERENCE

HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO CHILDREN'S DEVELOPMENT AND HEALTH

EFSA should in particular consider, and provide advice on the following aspects:

- Whether adequate information is provided on the characteristics of the food pertinent to the beneficial effect.
- Whether the beneficial effect of the food on the function is substantiated by generally accepted scientific evidence by taking into account the totality of the available scientific data, and by weighing the evidence. In this context EFSA is invited to comment on the nature and quality of the totality of the evidence provided according to consistent criteria.
- The specific importance of the food for the claimed effect. For functions affected by a large number of dietary factors whether a reference to a single food is scientifically pertinent.

In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent to which:

- the claimed effect of the food in the identified function is beneficial.
- a cause and effect relationship has been established between consumption of the food and the claimed effect in humans and whether the magnitude of the effect is related to the quantity consumed.
- where appropriate, the effect on the function is significant in relation to the quantity of the food proposed to be consumed and if this quantity could reasonably be consumed as part of a balanced diet.
- the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.
- the wordings used to express the claimed effect reflect the scientific evidence and complies with the criteria laid down in the Regulation.

When considering these elements EFSA should also provide advice, when appropriate:

- on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides for additional labelling requirements addressed to persons who should avoid using the food; and/or warnings for products that are likely to present a health risk if consumed to excess.

APPENDIX B

EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006.

APPENDIX C

Table 1. Main entry health claims related to iodine, including conditions of use from similar claims, as proposed in the Consolidated List.

ID	Food or Food constituent	Health Relationship	Proposed wording
273	Iodine	Neurological/ mental and cognitive development (including in-utero) <u>Clarification provided</u> Maintenance of neurological/mental and cognitive function.	-Iodine is needed/important for mental function; -Iodine plays a role in mental performance/ activity.
	<p>Conditions of use</p> <ul style="list-style-type: none"> - Schwangere - MINDESTENS 15 % RDA JE 100 G ODER 100 ML ODER JE PORTION GEMÄß 90/496/EWG - Kinder bis 10 Jahre. Amount of consumption: 5 bis 20 Mikrogramm (µg). Upper limit: 20 Mikrogramm (µg) - Erwachsene. Amount of consumption: 150 Mikrogramm (µg). Other condition: mind. 22,5 µg / 100g // 100 ml - MUST AT LEAST BE A SOURCE OF MINERAL/S AS PER ANNEX TO REGULATION 1924/2006 - Food supplement with 50-150mg of iodine in the daily dose - Names of nutrient/other substances and Quantity in Average daily serving: 150 micrograms iodine. Daily amount to be consumed to produce claimed effect: 150 microgram(s). Length of time after consumption for claimed effect to become apparent: habitual intake - Schwangere –Empfohlene tägliche Zufuhr 230 µg. 		
ID	Food or Food constituent	Health Relationship	Proposed wording
402	Jod <u>Clarification provided</u> iodine	Energiestoffwechsel <u>Clarification provided</u> energy metabolism	[In German :] Jod wird für den Energie-Stoffwechsel benötigt. <u>Clarification provided</u> Energy metabolism requires iodine.
	<p>Conditions of use</p> <ul style="list-style-type: none"> - No conditions of use provided 		
ID	Food or Food constituent	Health Relationship	Proposed wording
1237	Iodised salt	Body functions <u>Clarification provided</u> Salt iodisation contributes to thyroid gland function, by ensuring production of thyroid hormones	L'iodation du sel participe au bon fonctionnement de l'organisme <u>Clarification provided</u> - Iodised salt helps thyroid to function well. - Salt iodisation / iodised salt helps the thyroid gland to

			function well / contributes to the good functioning of the thyroid gland.
	Conditions of use - L'iodation du sel participe au bon fonctionnement de l'organisme		